GE To Resell Caradigm IAM Solution
By Megan Williams, contributing writer
GE has announced it will be offering Caradigm’s identity and access management (IAM) suite with Omnyx digital pathology solutions.
GE Healthcare announced that it will be reselling Caradigm’s Single Sign-On and Context Management Solutions System as a connectivity link between the Omnyx digital pathology platform (IDP) and designated anatomic pathology laboratory information systems (APLIS). The solution will be available in Canada, certain EU countries, and the United States, where the Omnyx IDP is used for in-vitro diagnostics in a specific clinical application, and can only be used in other applications for research purposes, according to MarketWatch.
The Path To Diagnosis
Omnyx and APLIS software solutions serve in the final step of the cancer diagnosis process, where the two are used to view whole slide images, and then render patient reports. The process begins when pathologists diagnose cancers through evaluation of tissues in the context of a patient’s history, then ordering further testing on the tissue if they find it necessary. Their findings are then delivered to an oncologist, who in turn, uses the pathologist report to determine treatment.
Collaboration
The primary goal of the collaboration with Caradigm is to streamline the workflow of pathologists. Caradigm’s Single Sign-On and Context Management Software from its IAM suite will connect with the Omnyx platform and the APLIS. Pathologists who use the solution will find more secure and quicker access to lab applications and patient data.
Mamar Gelaye, CEO of Omnyx says, “Digital pathology will enable pathologists to collaborate with other clinicians and patients. This level of connectivity is essential to derive patient-centered care and efficiency. Using Caradigm Single Sign-On and Context Management software in conjunction with Omnyx solutions, the pathologist will confidently be able to have the right access to the right application and the right data without interruption to their clinical workflow.”
From the Caradigm side, Sandy Murti, VP of partnerships and alliances for Caradigm adds, “Caradigm’s IAM products are designed exclusively to meet the complex needs of healthcare organizations challenged to make the right data available at the right time to the right caregivers. We’re excited to work with GE Healthcare and Omnyx to make it easier for pathologists to rapidly and securely access data as they provide care for cancer patients.”
Caradigm, a healthcare analytics and population health company launched on June 6, 2012, is the product of a joint venture between Microsoft and GE, and was originally intended to “combine the power of an open technology platform and collaborative clinical applications to bring together disparate patient data and transform it into intelligence,” according to GeekWire.